What happens when the workforce starts to read its own DNA?
A genetic result arrives long before any illness, and the institutions around it have no idea what to do.
Most people who learn they have a genetic variant are not sick that day. They are simply holding information about a version of themselves that may never arrive. A growing number of people are now living with a result like that, from a test they bought themselves or one their employer paid for, and they fold it into an ordinary life, including the part that happens at work, inside an institution that has no idea it exists.
The reading of the genome has become a process that feeds on itself. Sequencing got cheap, down to about a hundred dollars on the newest machines, so more people test, which makes more data, which trains the systems doing the reading, which surface more variants and more combinations of genes that older tests missed, which sends still more people to test. The number it produces keeps climbing. Look only at the cancer genes and about one in twenty adults has a serious, actionable variant; widen the view to cardiac and other conditions a genome can flag and it is closer to one in eight; and within about eighteen months I expect the broad figure to sit closer to one in six. The first two come from published studies and count different things, the last is a guess, and none of it is because more people are being born with these variants. The machines are getting better, and faster, at telling people what they have, well before anyone around them is ready to hear it.
The old system was built around sickness. A person developed symptoms, sought a diagnosis, and was treated, and the apparatus around them, doctors, insurers, employers, organized itself around that sequence. What is arriving now runs the other way. People are given information about diseases they do not have and may never get, years before anything happens, if it happens at all. Staying well is shifting from managing illness to managing information. Francis Collins, who led the public effort to sequence the human genome, named the size of it in 1998: “I believe that reading our blueprints, cataloguing our own instruction book, will be judged by history as more significant than even splitting the atom or going to the moon.” Demis Hassabis, who shared a Nobel for using AI to predict the shape of proteins, has said much the same from the other end of the arc, that the field spent decades on games and consumer software and is only now turning to biology, which he calls the single most important use of the technology.
The sequence itself barely moves. A person who has a germline variant was born with it and will keep it, because the tools that can rewrite a gene still reach only a short list of conditions, though families who already know they have a variant like BRCA can screen embryos through IVF to avoid passing it on. The writing of the genome is real, but it is slow, and it mostly touches the next generation.
These results arrive through a few doors, one of them the ordinary employer health plan. More than a hundred and fifty million Americans are covered through work, and at large companies roughly eighty percent of them sit in self-funded plans, where the company pays the medical bills from its own money and an insurer like UnitedHealthcare only runs the paperwork. The logo on the card belongs to the insurer, the money belongs to the company, and many of those same companies hand out the tests, through wellness vendors that screen workers at firms like SAP, GE, Salesforce, and Visa. Forty-four percent of large employers now cover genetic testing based on family history. It changes what a large share of a workforce knows about itself, while the employer is kept from the results.
What keeps the employer from seeing is the law. The Genetic Information Nondiscrimination Act, GINA, bars a company from requesting, requiring, or using an employee’s genetic information, and lets it see wellness-program results only in aggregate. The arrangement is strange almost by design. The company pays for the test, the employee learns something that may reshape years of their life and their family’s, and the company is not permitted to know who, or how many. The knowledge stays with the person. The cost does not. It surfaces where a workforce already feels strain, in the health plan, in leave, in a manager working around someone quietly managing a risk rather than an illness, and sometimes in that person’s own state of mind. None of it is hypothetical. Cancer has been the largest single driver of employer health costs for four years running, and companies expect those costs to rise about nine percent in 2026.
The test no longer comes only through the version an insurer paid for and vetted. The company that turned spitting into a tube into a household habit filed for bankruptcy in 2025, and the records of more than fifteen million people were sold, but the market it created did not close so much as scatter, into newer services still selling the same screening to anyone curious enough to mail in a sample. More people now meet this kind of news on their own, at a kitchen table, with no counselor on the other end of it. Most who have a variant still do not know it, nine in ten are unaware.
Almost everyone describing this shift has a stake in it. The companies that sell the tests frame it as early detection and savings. The lawyers treat it as a compliance problem, a matter of staying clear of GINA. The researchers ask whether workers trust the testing enough to take it. Each view is useful, and each is drawn from inside a single position, the one vantage that cannot see the whole field. The question that belongs to the institution itself, what it wants to be to a workforce coming to know it has serious inherited risk, is the one almost no one is asking. Even the people who think for a living about the future of work stay close to it without landing on it, writing about longer lives and longer careers rather than what those workers now know about their own bodies while the work goes on.
For now, the people holding these results mostly find each other quietly, in online or social media groups and in small networks built to match strangers who share the same variant. It is not hard to picture the next step, a version of that gathering forming inside a company, an employee group organized around precisely the risk the company is not allowed to see. Genetic information has never waited for an institution to be ready for it. It arrives one sample at a time, in living rooms and at kitchen tables, and walks into the building the next morning. The organizations that come through the next few years well will not be the ones that bought the best test, they will be the ones that worked out, before that group first met, what they wanted to be to a person who knows. This is a huge and important opportunity.